Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Int Immunopharmacol ; 134: 112215, 2024 Jun 15.
Artigo em Inglês | MEDLINE | ID: mdl-38744173

RESUMO

Camelid single-domain antibodies (VHH) represent a promising class of immunobiologicals for therapeutic applications due to their remarkable stability, specificity, and therapeutic potential. To enhance the effectiveness of antivenoms for snakebites, various methods have been explored to address limitations associated with serum therapy, particularly focusing on mitigating local damage and ensuring sustainable production. Our study aimed to characterize the pharmacological profile and neutralization capacity of anti-Phospholipase A2 (PLA2) monomeric VHH (Genbank accessions: KC329718). Using a post-envenoming mouse model, we used intravital microscopy to assess leukocyte influx, measured CK and LDH levels, and conducted a histopathology analysis to evaluate VHH KC329718's ability to neutralize myotoxic activity. Our findings demonstrated that VHH KC329718 exhibited heterogeneous distribution in muscle tissue. Treatment with VHH KC329718 reduced leukocyte influx caused by BthTX-I (a Lys-49 PLA2) by 28 %, as observed through intravital microscopy. When administered at a 1:10 ratio [venom or toxin:VHH (w/w)], VHH KC329718 significantly decreased myotoxicity, resulting in a 35-40 % reduction in CK levels from BthTX-I and BthTX-II (an Asp-49 PLA2) and a 60 % decrease in CK levels from B. jararacussu venom. LDH levels also showed reductions of 60%, 80%, and 60% induced by BthTX-I, BthTX-II, and B. jararacussu venom, respectively. Histological analysis confirmed the neutralization potential, displaying a significant reduction in tissue damage and inflammatory cell count in mice treated with VHH KC329718 post B. jararacussu venom inoculation. This study underscores the potential of monomeric anti-PLA2 VHH in mitigating myotoxic effects, suggesting a promising avenue for the development of new generation antivenoms to address current therapeutic limitations.


Assuntos
Antivenenos , Bothrops , Fosfolipases A2 , Anticorpos de Domínio Único , Mordeduras de Serpentes , Animais , Anticorpos de Domínio Único/imunologia , Mordeduras de Serpentes/tratamento farmacológico , Mordeduras de Serpentes/imunologia , Antivenenos/farmacologia , Antivenenos/uso terapêutico , Camundongos , Fosfolipases A2/metabolismo , Venenos de Crotalídeos/imunologia , Venenos de Crotalídeos/toxicidade , Masculino , Modelos Animais de Doenças , Músculo Esquelético/patologia , Músculo Esquelético/efeitos dos fármacos , Leucócitos/efeitos dos fármacos , Leucócitos/imunologia , Humanos , Creatina Quinase/sangue
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa